Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging

NCT04750473 is registered in ClinicalTrials.gov with Emory University as lead sponsor.

NCT NCT04750473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04750473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1 Feasibility Trial: Improved Staging of Lobular Breast Cancer With Novel Amino Acid Metabolic and Tumor Neovasculature Receptor Imaging
Lead sponsor
Emory University
Phase
Phase 1
Overall status
Completed
Start date
July 16, 2021
Completion date
March 21, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

anatomic stage iv breast cancer ajcc v8, invasive breast lobular carcinoma, metastatic breast lobular carcinoma, prognostic stage iv breast cancer ajcc v8